Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 Prevention

Dapivirine (DPV) and maraviroc (MVC) were formulated into aqueous gels designed to prevent mucosal HIV transmission

• From: Department for International Development
• Published: 1 January 2015

• Document Type: Journal Article
• Theme: Health
• Authors: Dezzutti, C.S., Rohan, L.C., Nuttall, J., Devlin, B., Brown, E.R., Lin Wang, Moncla, B., Teeple, E.A., Yandura, S.

Abstract

Dapivirine (DPV), a non-nucleoside reverse transcriptase inhibitor, and maraviroc (MVC), a CCR5 antagonist, were formulated into aqueous gels designed to prevent mucosal HIV transmission.

Citation

Dezzutti, C.S.; Yandura, S.; Lin Wang; Moncla, B.; Teeple, E.A.; Devlin, B.; Nuttall, J.; Brown, E.R.; Rohan, L.C. Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 Prevention. Pharmaceutical Research (2015) 32 (11) 3768-3781. [DOI: 10.1007/s11095-015-1738-7]

Links

Pharmacodynamic Activity of Dapivirine and Maraviroc Single Entity and Combination Topical Gels for HIV-1 Prevention

Published 1 January 2015